Hematopoiesis News Volume 13.09 | Mar 8 2022

    By
    Justin.choi
    -
    0
    24







    2020-03-08 | HN 13.09


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.09 – 8 March, 2022
    TOP STORY

    Stem Cell Architecture Drives Myelodysplastic Syndrome Progression and Predicts Response to Venetoclax-Based Therapy

    Through integrative molecular profiling of HSCs and progenitor cells in large patient cohorts, scientists found that myelodysplastic syndromes HSCs in two distinct differentiation states were maintained throughout the clinical course of the disease.
    [Nature Medicine]

    Full ArticlePress Release
    Webinar on Modeling arrhythmias using hPSC-derived cardiomyocytes
    PUBLICATIONSRanked by the impact factor of the journal

    Deletion of Grin1 in Mouse Megakaryocytes Reveals NMDA Receptor Role in Platelet Function and Proplatelet Formation

    Researchers found that Pf4-Grin1-/- mice had defects in megakaryopoiesis, thrombopoiesis and platelet function, which manifested as reduced platelet counts, lower rates of platelet production in the immune model of thrombocytopenia, and a prolonged tail bleeding time.
    [Blood]

    Abstract

    Tet-Mediated DNA Demethylation Regulates Specification of Hematopoietic Stem and Progenitor Cells during Mammalian Embryogenesis

    Scientists found that global or endothelial-specific loss of all three Tet enzymes immediately after gastrulation led to a reduced number of HSCs and progenitor cells and lethality in mid-gestation mouse embryos.
    [Science Advances]

    Full Article

    Obesity-Induced Galectin-9 Is a Therapeutic Target in B Cell Acute Lymphoblastic Leukemia

    Investigators showed that the adipocyte secretome upregulated the surface expression of Galectin-9 on human B-acute lymphoblastic leukemia cells which promoted chemoresistance.
    [Nature Communications]

    Full Article

    Exploiting Natural Killer Cell Engagers to Control Pediatric B Cell Precursor Acute Lymphoblastic Leukemia

    Researchers tested the in vitro effect of different natural killer (NK)-cell engagers, which triggered either NKp46 or NKp30 together with CD16A, and targeted either CD19 or CD20 to induce killing of pediatric B cell precursor acute lymphoblastic leukemia.
    [Cancer Immunology Research]

    Full Article

    Loss of IRF7 Accelerates Acute Myeloid Leukemia Progression and Induces VCAM1-VLA-4 Mediated Intracerebral Invasion

    The authors used MLL-AF9-induced AML mouse models with interferon regulatory factor 7 (IRF7) knockout or overexpression and xenograft mouse models to explore the intrinsic effects of IRF7 in AML.
    [Oncogene]

    Full Article

    NEDD4L Binds the Proteasome and Promotes Autophagy and Bortezomib Sensitivity in Multiple Myeloma

    Investigators reported an unexpected finding that the protein encoded by neural precursor cell-expressed developmentally downregulated gene 4L (NEDD4L), which was a HECT E3 ligase, bound the 19S proteasome, limiting its proteolytic function and enhancing autophagy.
    [Cell Death & Disease]

    Full Article

    PTEN/PI3K/Akt Pathway Alters Sensitivity of T Cell Acute Lymphoblastic Leukemia to L-Asparaginase

    The authors investigated the relationship amongst PTEN deletion, L-asparaginase sensitivity and glucose metabolism in T cell acute lymphoblastic leukemia cells.
    [Scientific Reports]

    Full Article

    Venetoclax Consolidation after Fixed-Duration Venetoclax plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia (HOVON 139/GiVe): Primary Endpoint Analysis of a Multicentre, Open-Label, Randomized, Parallel-Group, Phase II Trial

    Scientists determined the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status.
    [Lancet Haematology]

    Abstract

    Avatrombopag for Chemotherapy-Induced Thrombocytopenia in Patients with Non-Hematological Malignancies: An International, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

    Researchers evaluated avatrombopag, a thrombopoietin receptor agonist that increased platelet counts, in patients with non-hematological cancer and platelet counts lower than 50 ×109 cells per liter.
    [Lancet Haematology]

    Abstract
    Explore virtual support and resources to stay productive and connected with your field.
    REVIEWS

    Maladaptive Trained Immunity and Clonal Hematopoiesis as Potential Mechanistic Links between Periodontitis and Inflammatory Comorbidities

    The authors review two newly emerged concepts, trained innate immunity and clonal hematopoiesis of indeterminate potential, which together support a potential hypothesis on how periodontitis affects and is affected by comorbidities and why the susceptibility to periodontitis and comorbidities increases with aging.
    [Periodontology 2000]

    Abstract

    The Role of microRNAs in the Development, Progression and Drug Resistance of Chronic Myeloid Leukemia and Their Potential Clinical Significance

    Scientists discuss the potential role of miRNAs in the diagnosis, prognosis, and treatment response of chronic myeloid leukemia.
    [Life Sciences]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

    Harpoon Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC®, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy.
    [Harpoon Therapeutics, Inc.]

    Press Release

    TG Therapeutics Announces Extension of US FDA BLA/sNDA PDUFA Date for Ublituximab plus UKONIQ® (U2) to Treat Patients with CLL and SLL

    TG Therapeutics, Inc. announced the US FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date to June 25, 2022 for the Biologics License Application (BLA) and supplemental New Drug Application (sNDA) for ublituximab in combination with UKONIQ® as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
    [TG Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    EHA-SWG Scientific Meeting

    April 7 – April 9
    Rome, Italy & Virtual

    > See All Events

    JOB OPPORTUNITIES

    Senior Staff Scientist – Primary Cells

    Wellcome Sanger Institute – Cambridge, United Kingdom

    Full Project Scientist – Division of Cardiovascular Medicine

    The University of California, Davis – Davis, California, United States

    Researcher – Cancer Biology

    BC Cancer Research Institute – BC Cancer Research Institute

    Postdoctoral Scientist – Cellular Immunology/T Cell Therapy

    TU Dresden – Dresden, Germany

    Postdoctoral Research Fellow – Virology

    George Mason University – Prince William, Virginia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter